Jianjie Ma, Ph.D.

Dr. Jianjie Ma, Ph.D., is the Founder and Chief Executive Officer of TRIM-edicine. He is currently a University Professor at Robert Wood Johnson Medical School (RWJMS), and Director of a joint Graduate Program in Physiology and Integrative Biology between RWJMS and Rutgers University. Dr. Ma obtained his bachelor's degree in Physics from Wuhan University in China and Ph.D. in Physiology and Biophysics at Baylor College of Medicine. He serves on the editorial board of several major scientific journals and has authored or co-authored over 100 articles in peer-reviewed scientific journals. He was an Established Investigator from the American Heart Association, and has frequently served as a study section member for the National Institutes of Health. His research interests are in gene discovery and protein therapy in geriatric medicine, tissue repair, muscular dystrophy, cardiovascular disease, and cancer biology.

Noah Weisleder, Ph.D.

Dr. Noah Weisleder, Ph.D., is a co-founder of, and serves as the Chief Scientific Officer for, TRIM-edicine. Dr. Weisleder received his bachelor’s degree with distinction from Worcester Polytechnic Institute, and his Ph.D. in Molecular and Cellular Biology from Baylor College of Medicine. Dr. Weisleder is a member of several scientific societies, including the American Association for the Advancement of Science (AAAS), the American Heart Association – Council on Basic Cardiovascular Sciences, the American Society of Cell Biologists, the Biophysical Society, the International Society for Heart Research, and the New York Academy of Sciences. He has authored or co-authored several publications based upon his doctoral and post-doctoral work in peer-reviewed scientific journals, including Nature, Nature Cell Biology, PNAS, Journal of Cell Biology and Journal of Cell Science.

Scientific Advisory Board

John Kostis, M.D.

John B. Kostis, M.D. is the John G. Detwiler Professor of Cardiology and Chairman of the Department of Medicine at UMDNJ-Robert Wood Johnson Medical School. He also serves as Chief of Medical Service at Robert Wood Johnson University Hospital. Dr. Kostis developed state of the art tertiary cardiology in New Brunswick, established clinical research in cardiology at Robert Wood Johnson Medical School, participated in the study and development of over 100 pharmacologic agents and devices and held leadership positions in large clinical trials sponsored by the NIH and the industry. He has published six books, over 300 papers and chapters, and serves as Associate Editor of Cardiology and other scientific journals. Dr. Kostis’ research interests include clinical trials, cardiovascular pharmacology and biomedical engineering.

Virginia Barnes, D.D.S.

Virginia Monsul Barnes, D.D.S, is the Manager of Clinical Research at the Colgate Palmolive Company Technology Center in New Jersey. She received a Master of Science degree in Physiology from UMDNJ-Robert Wood Johnson Medical School and her Doctor of Dental Surgery from Georgetown University School of Dentistry. At Colgate, Dr. Barnes manages the proof of concept clinical program investigating new technologies for oral therapeutic products. This program conducts traditional human clinical research and develops new clinical methodologies. Additionally the program explores the use of basic research in combination with clinical research in an effort to enhance the technology development, to improve the predictability of clinical studies, and to deliver more targeted and sophisticated documentation for product claims.

Outside Counsel

Bryan Zerhusen, J.D., Ph.D.

As an associate with McCarter & English, LLP, Dr. Zerhusen's practice includes all aspects of patent and trademark prosecution, licensing, due diligence, clearance and patentability opinions, and patent infringement litigation support concentrating on scientific/medical devices, biotechnology, pharmaceuticals, and chemicals. Dr. Zerhusen's clients include individual researchers, biotech companies, universities, as well as large chemical and pharmaceutical companies. Dr. Zerhusen's prior scientific training includes a postdoctoral fellowship at Case Western Reserve University, which was focused on molecular and physiological origins of cystic fibrosis, as well as a number of years as a Research Scientist for a mid-sized biopharmaceutical company where he utilized genomic and proteomic techniques to identify and characterize therapeutic candidates/targets over all major disease areas.